Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMARETTO: Subcutaneous Infliximab After Previous Intravenous Dose Optimization
2023-508166-15-00Phase 4Authorised
- Sponsor
- Belgian IBD Research and Development
- Start
- Apr 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of infliximab in autoimmune colitis, Crohn's disease and inflammatory bowel disease (IBD), sponsored by Belgian IBD Research and Development. Primary endpoint: Maintenance of steroid-free clinical and biological remission without treatment optimization at week 52. Planned start Apr 2024; status: authorised.
02
Drugs
infliximab
03
Conditions
autoimmune colitisCrohn's diseaseinflammatory bowel disease (IBD)
Beyond the preview
Go deeper on 2023-508166-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508166-15-00.